Severe Acute Pancreatitis

Severe acute pancreatitis (SAP) is a lifethreatening inflammatory condition of the pancreas that can rapidly progress to multiorgan failure. Although it accounts for only 1520% of all acute pancreatitis episodes, it is responsible for the majority of morbidity, mortality, and healthcare costs associated with the disease.

1. Definition & Classification

Acute pancreatitis is diagnosed when at least two of the following three criteria are met:

• Abdominal pain characteristic of pancreatitis (persistent, epigastric, radiating to the back).
• Serum amylase or lipase 3upper limit of normal.
• Imaging findings typical of pancreatic inflammation.

Severity is graded according to the 2012 Revised Atlanta Classification:

• Mild no organ failure, no local or systemic complications.
• Moderately severe transient organ failure (<48h) or local complications (e.g., peripancreatic fluid collections).
• Severe persistent organ failure (>48h), which may involve respiratory, cardiovascular, or renal systems.

2. Epidemiology

3. Pathophysiology

The initial insult triggers premature activation of pancreatic enzymes within the pancreas, leading to autodigestion, inflammation, and microvascular injury. This cascade releases cytokines (TNF, IL1, IL6) and activates complement, producing a systemic inflammatory response syndrome (SIRS). In severe disease, SIRS progresses to a compensatory antiinflammatory response syndrome (CARS), predisposing to infection, necrosis, and multiorgan dysfunction.

4. Clinical Presentation

• Acute, severe epigastric pain radiating to the back.
• Nausea, vomiting, abdominal distension.
• Signs of systemic inflammation: fever, tachycardia, hypotension.
• Respiratory compromise (e.g., Acute Respiratory Distress Syndrome).
• Renal impairment, altered mental status in advanced cases.

5. Diagnostic Workup

5.1 Laboratory Tests

• Serum amylase/lipase elevated early, may fall after 4872h.
• Complete blood count leukocytosis, possible anemia.
• Metabolic panel electrolyte disturbances (hypocalcaemia), renal function.
• CRP useful for predicting severity; >150mg/L after 48h suggests severe disease.
• Blood urea nitrogen, lactate markers of hypoperfusion.
• Liver function tests help identify gallstone etiology.

5.2 Imaging

• Contrastenhanced CT (CECT) gold standard for assessing necrosis, performed 72h after symptom onset.
• Transabdominal ultrasound firstline to detect gallstones and biliary obstruction.
• Magnetic resonance cholangiopancreatography (MRCP) useful when CT is equivocal or for detailed ductal evaluation.

5.3 Scoring Systems for Early Severity Prediction

6. Management

6.1 Initial Resuscitation

• Goaldirected fluid therapy: 250500mL/h of isotonic crystalloids (Ringers lactate preferred) for the first 1224h, guided by urine output (0.5mL/kg/h), MAP65mmHg, and hematocrit.
• Pain control: IV opioids (e.g., hydromorphone) titrated to relieve pain while maintaining respiratory drive.
• NPO (nil per os) for 2448h, with early enteral nutrition once tolerated (preferably within 2448h).
• Correct electrolyte imbalances especially calcium and magnesium.

6.2 Specific Therapies

• Antibiotics not indicated prophylactically; reserve for infected necrosis confirmed by fineneedle aspiration or gas on imaging.
• Pancreatic enzyme inhibition somatostatin analogues have no proven benefit and are not routinely recommended.
• ERCP indicated urgently (within 24h) for cholangitis or biliary obstruction.

6.3 Nutritional Support

Enteral feeding (nasogastric or nasojejunal) reduces infectious complications compared with parenteral nutrition. If oral intake is impossible after 72h, start a lowfat polymeric formula; consider a semielemental formula if intolerance persists.

6.4 Management of Complications

• Pancreatic necrosis Monitor with repeat imaging; if infected, percutaneous drainage or endoscopic transluminal drainage is firstline. Vascular necrosectomy is reserved for persistent sepsis.
• Fluid collections Differentiate between acute peripancreatic fluid collections, pseudocysts, and walledoff necrosis; intervene only when symptomatic or infected.
• Organ failure ICU care with ventilatory support, renal replacement therapy, and vasoactive agents as needed.

6.5 Surgical Intervention

Operative necrosectomy is now delayed (usually >4weeks) to allow demarcation of necrotic tissue, reducing morbidity. Minimally invasive approaches (videoassisted retroperitoneal debridement, endoscopic necrosectomy) have become standard in many centres.

7. Prognosis & Followup

Early identification of severe disease and aggressive supportive care are the main determinants of outcome. Mortality peaks within the first two weeks, primarily due to respiratory failure and sepsis. Longterm sequelae include pancreatic exocrine insufficiency, diabetes mellitus, and chronic abdominal pain.

Patients should be followed up for:

• Resolution of fluid collections (repeat imaging at 612weeks).
• Pancreatic function: fecal elastase and fasting glucose.
• Lifestyle counseling abstinence from alcohol, lowfat diet, and management of hypertriglyceridaemia.

8. Key Points for Clinicians

1. Recognize severe acute pancreatitis early using clinical criteria and validated scoring systems.
2. Initiate aggressive fluid resuscitation and pain control within the first 24h.
3. Reserve antibiotics for proven infected necrosis; avoid prophylactic use.
4. Prefer early enteral nutrition over parenteral feeding.
5. Use minimally invasive drainage for infected necrosis before considering surgery.
6. Monitor for multiorgan failure; involve criticalcare specialists promptly.

This information is intended for educational purposes and should not replace individual clinical judgment.